Immunotherapy before surgery for stage II-III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at using immunotherapy before surgery for stage II-III lung cancer. It aims to find markers that predict how well this treatment works, potentially leading to more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer at stage II or III
- You do not have an EGFR or ALK gene mutation
- You are 18 years of age or older
- You are planning to receive immunotherapy before your cancer surgery
- Your daily function is good (able to care for yourself and be up and about)
- You have not had chemotherapy, radiation, or other cancer treatment in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether two immunotherapy drugs (nivolumab and ipilimumab) given before surgery can help treat non-small cell lung cancer that is stage II to IIIA. It's for people whose tumors are removable and who haven't had prior cancer treatment.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
Hear when a new NSCLC Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.